

ICD-10 Procedure Coding System (ICD-10-PCS) 2027 Tables Addenda

ICD-10-PCS Tables that have changed this year are shown in table format in the pages below. Click on a bookmark to go to a specific table.

Each table shown in the addenda replaces the table from the previous year.

028

No change	<i>Section</i> 0 Medical and Surgical			
	<i>Body System</i> 2 Heart and Great Vessels			
	<i>Operation</i> 8 Division: Cutting into a body part, without draining fluids and/or gases from the body part, in order to separate or transect a body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
No change	8 Conduction Mechanism 9 Chordae Tendineae D Papillary Muscle	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	Z No Device	Z No Qualifier
FY2027	F Aortic Valve G Mitral Valve	3 Percutaneous	Z No Device	0 Native Leaflet 1 Prosthetic Leaflet

ORG

No change	Section 0 Medical and Surgical Body System R Upper Joints Operation G Fusion: Joining together portions of an articular body part rendering the articular body part immobile			
Heading	Body Part	Approach	Device	Qualifier
FY2027	0 Occipital-cervical Joint 1 Cervical Vertebral Joint 2 Cervical Vertebral Joints, 2 or more 4 Cervicothoracic Vertebral Joint 6 Thoracic Vertebral Joint 7 Thoracic Vertebral Joints, 2 to 7 8 Thoracic Vertebral Joints, 8 or more	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	0 Anterior Approach, Anterior Column 1 Posterior Approach, Posterior Column J Posterior Approach, Anterior Column
FY2027	0 Occipital-cervical Joint 1 Cervical Vertebral Joint 2 Cervical Vertebral Joints, 2 or more 4 Cervicothoracic Vertebral Joint 6 Thoracic Vertebral Joint 7 Thoracic Vertebral Joints, 2 to 7 8 Thoracic Vertebral Joints, 8 or more	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	A Interbody Fusion Device	0 Anterior Approach, Anterior Column J Posterior Approach, Anterior Column
FY2027	A Thoracolumbar Vertebral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	0 Anterior Approach, Anterior Column 1 Posterior Approach, Posterior Column J Posterior Approach, Anterior Column
FY2027	A Thoracolumbar Vertebral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	A Interbody Fusion Device E Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed	0 Anterior Approach, Anterior Column J Posterior Approach, Anterior Column
No change	C Temporomandibular Joint, Right D Temporomandibular Joint, Left E Sternoclavicular Joint, Right F Sternoclavicular Joint, Left G Acromioclavicular Joint, Right H Acromioclavicular Joint, Left J Shoulder Joint, Right K Shoulder Joint, Left	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	4 Internal Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	Z No Qualifier

No change

L Elbow Joint, Right M Elbow Joint, Left N Wrist Joint, Right P Wrist Joint, Left Q Carpal Joint, Right R Carpal Joint, Left S Carpometacarpal Joint, Right T Carpometacarpal Joint, Left U Metacarpophalangeal Joint, Right V Metacarpophalangeal Joint, Left W Finger Phalangeal Joint, Right X Finger Phalangeal Joint, Left	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	3 Internal Fixation Device, Sustained Compression 4 Internal Fixation Device 5 External Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	Z No Qualifier
--	--	--	-----------------------

OSG

No change	Section 0 Medical and Surgical			
	Body System S Lower Joints			
	Operation G Fusion: Joining together portions of an articular body part rendering the articular body part immobile			
Heading	Body Part	Approach	Device	Qualifier
No change	0 Lumbar Vertebral Joint 1 Lumbar Vertebral Joints, 2 or more 3 Lumbosacral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	0 Anterior Approach, Anterior Column 1 Posterior Approach, Posterior Column J Posterior Approach, Anterior Column
FY2027	0 Lumbar Vertebral Joint 1 Lumbar Vertebral Joints, 2 or more 3 Lumbosacral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	A Interbody Fusion Device E Interbody Fusion Device, Custom-Made Anatomically and Virtually Designed	0 Anterior Approach, Anterior Column J Posterior Approach, Anterior Column
No change	5 Sacrococcygeal Joint 7 Sacroiliac Joint, Right 8 Sacroiliac Joint, Left	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	4 Internal Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	Z No Qualifier
No change	9 Hip Joint, Right B Hip Joint, Left C Knee Joint, Right D Knee Joint, Left F Ankle Joint, Right G Ankle Joint, Left H Tarsal Joint, Right J Tarsal Joint, Left K Tarsometatarsal Joint, Right L Tarsometatarsal Joint, Left M Metatarsal-Phalangeal Joint, Right N Metatarsal-Phalangeal Joint, Left P Toe Phalangeal Joint, Right Q Toe Phalangeal Joint, Left	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	3 Internal Fixation Device, Sustained Compression 4 Internal Fixation Device 5 External Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	Z No Qualifier

0W9

No change	Section 0 Medical and Surgical			
	Body System W Anatomical Regions, General			
	Operation 9 Drainage: Taking or letting out fluids and/or gases from a body part			
Heading	Body Part	Approach	Device	Qualifier
FY2027	0 Head 1 Cranial Cavity 2 Face 3 Oral Cavity and Throat 4 Upper Jaw 5 Lower Jaw 8 Chest Wall D Pericardial Cavity F Abdominal Wall G Peritoneal Cavity H Retroperitoneum K Upper Back L Lower Back M Perineum, Male N Perineum, Female	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	0 Drainage Device	Z No Qualifier
FY2027	0 Head 1 Cranial Cavity 2 Face 3 Oral Cavity and Throat 4 Upper Jaw 5 Lower Jaw 8 Chest Wall D Pericardial Cavity F Abdominal Wall G Peritoneal Cavity H Retroperitoneum K Upper Back L Lower Back M Perineum, Male N Perineum, Female	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	Z No Device	X Diagnostic Z No Qualifier
No change	6 Neck J Pelvic Cavity	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	0 Drainage Device	Z No Qualifier
No change	6 Neck J Pelvic Cavity	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	X Diagnostic Z No Qualifier
FY2027	9 Pleural Cavity, Right B Pleural Cavity, Left C Mediastinum	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	0 Drainage Device	3 Active Mechanical Clearance Z No Qualifier
FY2027	9 Pleural Cavity, Right B Pleural Cavity, Left C Mediastinum	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	Z No Device	X Diagnostic Z No Qualifier

302

No change	<i>Section</i> 3 Administration			
	<i>Body System</i> 0 Circulatory			
	<i>Operation</i> 2 Transfusion: Putting in blood or blood products			
Heading				
	<i>Body System / Region</i>	<i>Approach</i>	<i>Substance</i>	<i>Qualifier</i>
No change	3 Peripheral Vein 4 Central Vein	3 Percutaneous	C Hematopoietic Stem/Progenitor Cells, Genetically Modified	0 Autologous
No change	3 Peripheral Vein 4 Central Vein	3 Percutaneous	D Pathogen Reduced Cryoprecipitated Fibrinogen Complex	1 Nonautologous
No change	3 Peripheral Vein 4 Central Vein	3 Percutaneous	G Bone Marrow X Stem Cells, Cord Blood Y Stem Cells, Hematopoietic	0 Autologous 2 Allogeneic, Related 3 Allogeneic, Unrelated 4 Allogeneic, Unspecified
FY2027	3 Peripheral Vein 4 Central Vein	3 Percutaneous	H Whole Blood J Serum Albumin K Frozen Plasma L Fresh Plasma M Plasma Cryoprecipitate N Red Blood Cells P Frozen Red Cells Q White Cells R Platelets T Fibrinogen V Antihemophilic Factors W Factor IX	0 Autologous 1 Nonautologous
FY2027	3 Peripheral Vein 4 Central Vein	3 Percutaneous	S Globulin	0 Autologous 1 Nonautologous 5 Immune Globulin, High-Dose
No change	3 Peripheral Vein 4 Central Vein	3 Percutaneous	U Stem Cells, T-cell Depleted Hematopoietic	2 Allogeneic, Related 3 Allogeneic, Unrelated 4 Allogeneic, Unspecified
No change	7 Products of Conception, Circulatory	3 Percutaneous 7 Via Natural or Artificial Opening	H Whole Blood J Serum Albumin K Frozen Plasma L Fresh Plasma M Plasma Cryoprecipitate N Red Blood Cells P Frozen Red Cells Q White Cells R Platelets S Globulin T Fibrinogen V Antihemophilic Factors W Factor IX	1 Nonautologous
No change	8 Vein	3 Percutaneous	B 4-Factor Prothrombin Complex Concentrate	1 Nonautologous
No change	A Bone Marrow	3 Percutaneous	H Whole Blood J Serum Albumin K Frozen Plasma L Fresh Plasma N Red Blood Cells P Frozen Red Cells R Platelets	0 Autologous 1 Nonautologous

3E0

No change	<i>Section</i>	3	Administration	
	<i>Body System</i>	E	Physiological Systems and Anatomical Regions	
	<i>Operation</i>	0	Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products	
Heading	<i>Body System / Region</i>	<i>Approach</i>	<i>Substance</i>	<i>Qualifier</i>
No change	0 Skin and Mucous Membranes	X External	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	0 Skin and Mucous Membranes	X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	0 Skin and Mucous Membranes	X External	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine B Anesthetic Agent K Other Diagnostic Substance M Pigment N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
FY2027	0 Skin and Mucous Membranes	X External	G Other Therapeutic Substance	C Other Substance F Other Enzymatic/Chemical Agent
No change	1 Subcutaneous Tissue	0 Open	2 Anti-infective	A Anti-Infective Envelope
No change	1 Subcutaneous Tissue	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	1 Subcutaneous Tissue	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective A Anti-Infective Envelope
No change	1 Subcutaneous Tissue	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	1 Subcutaneous Tissue	3 Percutaneous	4 Serum, Toxoid and Vaccine	0 Influenza Vaccine Z No Qualifier
No change	1 Subcutaneous Tissue	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	1 Subcutaneous Tissue	3 Percutaneous	V Hormone	G Insulin J Other Hormone
FY2027	1 Subcutaneous Tissue	X External	G Other Therapeutic Substance	F Other Enzymatic/Chemical Agent
No change	2 Muscle	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	2 Muscle	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	2 Muscle	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	2 Muscle	3 Percutaneous	4 Serum, Toxoid and Vaccine	0 Influenza Vaccine Z No Qualifier
No change	2 Muscle	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	3 Peripheral Vein	0 Open	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	3 Peripheral Vein	0 Open	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	3 Peripheral Vein	0 Open	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	3 Peripheral Vein	0 Open	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	3 Peripheral Vein	0 Open	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption
No change	3 Peripheral Vein	0 Open	U Pancreatic Islet Cells	0 Autologous 1 Nonautologous
No change	3 Peripheral Vein	0 Open	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	3 Peripheral Vein	0 Open	W Immunotherapeutic	K Immunostimulator L Immunosuppressive
No change	3 Peripheral Vein	3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	3 Peripheral Vein	3 Percutaneous	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	3 Peripheral Vein	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	3 Peripheral Vein	3 Percutaneous	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance A Stem Cells, Embryonic F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	3 Peripheral Vein	3 Percutaneous	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption Q Glucarpidase R Other Therapeutic Monoclonal Antibody
No change	3 Peripheral Vein	3 Percutaneous	U Pancreatic Islet Cells	0 Autologous 1 Nonautologous
No change	3 Peripheral Vein	3 Percutaneous	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	3 Peripheral Vein	3 Percutaneous	W Immunotherapeutic	K Immunostimulator L Immunosuppressive
No change	4 Central Vein	0 Open	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	4 Central Vein	0 Open	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	4 Central Vein	0 Open	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	4 Central Vein	0 Open	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	4 Central Vein	0 Open	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption
No change	4 Central Vein	0 Open	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	4 Central Vein	0 Open	W Immunotherapeutic	K Immunostimulator L Immunosuppressive

No change	4 Central Vein	3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	4 Central Vein	3 Percutaneous	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	4 Central Vein	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	4 Central Vein	3 Percutaneous	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance A Stem Cells, Embryonic F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	4 Central Vein	3 Percutaneous	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption Q Glucarpidase R Other Therapeutic Monoclonal Antibody
No change	4 Central Vein	3 Percutaneous	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	4 Central Vein	3 Percutaneous	W Immunotherapeutic	K Immunostimulator L Immunosuppressive
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier

No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	W Immunotherapeutic	K Immunostimulator L Immunosuppressive
No change	7 Coronary Artery 8 Heart	0 Open 3 Percutaneous	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	7 Coronary Artery 8 Heart	0 Open 3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	7 Coronary Artery 8 Heart	0 Open 3 Percutaneous	K Other Diagnostic Substance P Platelet Inhibitor	Z No Qualifier
No change	7 Coronary Artery 8 Heart	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	9 Nose	3 Percutaneous 7 Via Natural or Artificial Opening X External	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	9 Nose	3 Percutaneous 7 Via Natural or Artificial Opening X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	9 Nose	3 Percutaneous 7 Via Natural or Artificial Opening X External	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	9 Nose	3 Percutaneous 7 Via Natural or Artificial Opening X External	G Other Therapeutic Substance	C Other Substance
No change	A Bone Marrow	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	A Bone Marrow	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	B Ear	3 Percutaneous 7 Via Natural or Artificial Opening X External	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	B Ear	3 Percutaneous 7 Via Natural or Artificial Opening X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	B Ear	3 Percutaneous 7 Via Natural or Artificial Opening X External	3 Anti-inflammatory B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	B Ear	3 Percutaneous 7 Via Natural or Artificial Opening X External	G Other Therapeutic Substance	C Other Substance

No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	3 Anti-inflammatory B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance M Pigment N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	G Other Therapeutic Substance	C Other Substance
No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	S Gas	F Other Gas
No change	D Mouth and Pharynx	3 Percutaneous 7 Via Natural or Artificial Opening X External	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	D Mouth and Pharynx	3 Percutaneous 7 Via Natural or Artificial Opening X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	D Mouth and Pharynx	3 Percutaneous 7 Via Natural or Artificial Opening X External	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives R Antiarrhythmic T Destructive Agent	Z No Qualifier
No change	D Mouth and Pharynx	3 Percutaneous 7 Via Natural or Artificial Opening X External	G Other Therapeutic Substance	C Other Substance
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	S Gas	F Other Gas
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	S Gas	D Nitric Oxide F Other Gas
No change	F Respiratory Tract	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance

No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	S Gas	F Other Gas
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	U Pancreatic Islet Cells	0 Autologous 1 Nonautologous
No change	J Biliary and Pancreatic Tract	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	L Pleural Cavity	0 Open	5 Adhesion Barrier	Z No Qualifier
No change	L Pleural Cavity	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	L Pleural Cavity	3 Percutaneous	1 Thrombolytic	7 Other Thrombolytic
No change	L Pleural Cavity	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	L Pleural Cavity	3 Percutaneous	3 Anti-inflammatory 5 Adhesion Barrier 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	L Pleural Cavity	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	L Pleural Cavity	3 Percutaneous	S Gas	F Other Gas

No change	L Pleural Cavity	4 Percutaneous Endoscopic	5 Adhesion Barrier	Z No Qualifier
No change	L Pleural Cavity	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	L Pleural Cavity	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	L Pleural Cavity	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	M Peritoneal Cavity	0 Open	5 Adhesion Barrier	Z No Qualifier
No change	M Peritoneal Cavity	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody Y Hyperthermic
No change	M Peritoneal Cavity	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	M Peritoneal Cavity	3 Percutaneous	3 Anti-inflammatory 5 Adhesion Barrier 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	M Peritoneal Cavity	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	M Peritoneal Cavity	3 Percutaneous	S Gas	F Other Gas
No change	M Peritoneal Cavity	4 Percutaneous Endoscopic	5 Adhesion Barrier	Z No Qualifier
No change	M Peritoneal Cavity	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	M Peritoneal Cavity	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	M Peritoneal Cavity	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	P Female Reproductive	0 Open	5 Adhesion Barrier	Z No Qualifier
No change	P Female Reproductive	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	P Female Reproductive	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	P Female Reproductive	3 Percutaneous	3 Anti-inflammatory 5 Adhesion Barrier 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance L Sperm N Analgesics, Hypnotics, Sedatives T Destructive Agent V Hormone	Z No Qualifier

No change	P Female Reproductive	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	P Female Reproductive	3 Percutaneous	Q Fertilized Ovum	0 Autologous 1 Nonautologous
No change	P Female Reproductive	3 Percutaneous	S Gas	F Other Gas
No change	P Female Reproductive	4 Percutaneous Endoscopic	5 Adhesion Barrier	Z No Qualifier
No change	P Female Reproductive	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	P Female Reproductive	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	P Female Reproductive	7 Via Natural or Artificial Opening	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	P Female Reproductive	7 Via Natural or Artificial Opening	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance L Sperm N Analgesics, Hypnotics, Sedatives T Destructive Agent V Hormone	Z No Qualifier
No change	P Female Reproductive	7 Via Natural or Artificial Opening	G Other Therapeutic Substance	C Other Substance
No change	P Female Reproductive	7 Via Natural or Artificial Opening	Q Fertilized Ovum	0 Autologous 1 Nonautologous
No change	P Female Reproductive	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	S Gas	F Other Gas
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance A Stem Cells, Embryonic B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	E Stem Cells, Somatic	0 Autologous 1 Nonautologous
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	S Gas	F Other Gas
No change	Q Cranial Cavity and Brain	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	Q Cranial Cavity and Brain	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	R Spinal Canal	0 Open	A Stem Cells, Embryonic	Z No Qualifier
No change	R Spinal Canal	0 Open	E Stem Cells, Somatic	0 Autologous 1 Nonautologous
No change	R Spinal Canal	3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	R Spinal Canal	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	R Spinal Canal	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance A Stem Cells, Embryonic B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	R Spinal Canal	3 Percutaneous	E Stem Cells, Somatic	0 Autologous 1 Nonautologous
No change	R Spinal Canal	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	R Spinal Canal	3 Percutaneous	S Gas	F Other Gas
No change	R Spinal Canal	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	S Epidural Space	3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	S Epidural Space	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	S Epidural Space	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	S Epidural Space	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	S Epidural Space	3 Percutaneous	S Gas	F Other Gas
No change	S Epidural Space	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	T Peripheral Nerves and Plexi X Cranial Nerves	3 Percutaneous	3 Anti-inflammatory B Anesthetic Agent T Destructive Agent	Z No Qualifier
No change	T Peripheral Nerves and Plexi X Cranial Nerves	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	U Joints	0 Open	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	U Joints	0 Open	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance
No change	U Joints	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	U Joints	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	U Joints	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	U Joints	3 Percutaneous	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance
No change	U Joints	3 Percutaneous	S Gas	F Other Gas
No change	U Joints	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	V Bones	0 Open	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance
No change	V Bones	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	V Bones	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	V Bones	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	V Bones	3 Percutaneous	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance
No change	V Bones	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	W Lymphatics	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	W Lymphatics	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	W Lymphatics	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	W Lymphatics	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	Y Pericardial Cavity	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	Y Pericardial Cavity	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	Y Pericardial Cavity	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	Y Pericardial Cavity	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	Y Pericardial Cavity	3 Percutaneous	S Gas	F Other Gas
No change	Y Pericardial Cavity	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	Y Pericardial Cavity	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	Y Pericardial Cavity	7 Via Natural or Artificial Opening	S Gas	F Other Gas

5A0

No change	Section 5 Extracorporeal or Systemic Assistance and Performance			
	Body System A Physiological Systems			
	Operation 0 Assistance: Taking over a portion of a physiological function by extracorporeal means			
Heading	Body System	Duration	Function	Qualifier
No change	2 Cardiac	1 Intermittent	1 Output	0 Balloon Pump 5 Pulsatile Compression 6 Other Pump D Impeller Pump
No change	2 Cardiac	2 Continuous	1 Output	0 Balloon Pump 5 Pulsatile Compression 6 Other Pump D Impeller Pump E Blood Flow Modulator
No change	2 Cardiac	2 Continuous	2 Oxygenation	C Supersaturated
FY2027	5 Circulatory	1 Intermittent	2 Oxygenation	1 Hyperbaric
FY2027	5 Circulatory	2 Continuous	2 Oxygenation	1 Hyperbaric
FY2027	5 Circulatory	2 Continuous	7 Decompression	D Impeller Pump
No change	5 Circulatory	A Intraoperative	0 Filtration	L Peripheral Veno-venous
No change	5 Circulatory	A Intraoperative	6 Cerebral Embolic Filtration	M Single Capture Filter N Dual Capture Filter P Single Deflection Filter Q Extracorporeal Flow Reversal Circuit
No change	9 Respiratory	2 Continuous	0 Filtration	Z No Qualifier
No change	9 Respiratory	3 Less than 24 Consecutive Hours 4 24-96 Consecutive Hours 5 Greater than 96 Consecutive Hours	5 Ventilation	7 Continuous Positive Airway Pressure 8 Intermittent Positive Airway Pressure 9 Continuous Negative Airway Pressure A High Flow/Velocity Cannula B Intermittent Negative Airway Pressure Z No Qualifier
No change	9 Respiratory	B Less than 8 Consecutive Hours C 8-24 Consecutive Hours D Greater than 24 Consecutive Hours	5 Ventilation	K Intubated Prone Positioning

5A1

No change	Section 5 Extracorporeal or Systemic Assistance and Performance Body System A Physiological Systems Operation 1 Performance: Completely taking over a physiological function by extracorporeal means			
Heading	Body System	Duration	Function	Qualifier
No change	2 Cardiac	0 Single	1 Output	2 Manual
No change	2 Cardiac	1 Intermittent	3 Pacing	Z No Qualifier
No change	2 Cardiac	2 Continuous	1 Output	J Automated Z No Qualifier
No change	2 Cardiac	2 Continuous	3 Pacing	Z No Qualifier
No change	5 Circulatory	2 Continuous A Intraoperative	2 Oxygenation	F Membrane, Central G Membrane, Peripheral Veno-arterial H Membrane, Peripheral Veno-venous
No change	9 Respiratory	0 Single	5 Ventilation	4 Nonmechanical
No change	9 Respiratory	3 Less than 24 Consecutive Hours 4 24-96 Consecutive Hours 5 Greater than 96 Consecutive Hours	5 Ventilation	Z No Qualifier
No change	C Biliary	0 Single 6 Multiple	0 Filtration	Z No Qualifier
FY2027	D Urinary	7 Intermittent, Less than 6 Hours Per Day 8 Prolonged Intermittent, 6-18 hours Per Day 9 Continuous, Greater than 18 hours Per Day	0 Filtration	1 Selective Cytophoresis Z No Qualifier

B85

FY2027	<i>Section</i> B Imaging			
	<i>Body System</i> 8 Eye			
	<i>Type</i> 5 Other Imaging: Other specified modality for visualizing a body part			
Heading	<i>Body Part</i>	<i>Contrast</i>	<i>Qualifier</i>	<i>Qualifier</i>
FY2027	A Choroid, Right B Choroid, Left G Retinal Vessel, Right H Retinal Vessel, Left	2 Fluorescing Agent	Z None	Z None

X0H

No change	<i>Section</i> X New Technology			
	<i>Body System</i> 0 Nervous System			
	<i>Operation</i> H Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	K Sphenopalatine Ganglion	3 Percutaneous	Q Neurostimulator Lead	8 New Technology Group 8
FY2027	Q Vagus Nerve	0 Open	5 Leadless Neurostimulator Generator	C New Technology Group 12
No change	Q Vagus Nerve	3 Percutaneous	R Neurostimulator Lead with Paired Stimulation System	8 New Technology Group 8

X27

No change	Section X New Technology			
	Body System 2 Cardiovascular System			
	Operation 7 Dilation: Expanding an orifice or the lumen of a tubular body part			
Heading	Body Part	Approach	Device / Substance / Technology	Qualifier
No change	2 Inferior Vena Cava and Iliacaval Confluence	3 Percutaneous	C Intraluminal Device, Open-structure Polymer Lattice	B New Technology Group 11
No change	3 Pulmonary Artery, Right 4 Pulmonary Artery, Left	3 Percutaneous	9 Intraluminal Device, Expandable	B New Technology Group 11
No change	5 Subclavian Vein, Right 6 Subclavian Vein, Left 7 Axillary Vein, Right 8 Axillary Vein, Left 9 Brachial Vein, Right A Brachial Vein, Left B Basilic Vein, Right C Basilic Vein, Left D Cephalic Vein, Right E Cephalic Vein, Left	3 Percutaneous	5 Intraluminal Device, Cell Impermeable	B New Technology Group 11
FY2027	P Anterior Tibial Artery, Right	3 Percutaneous	N Intraluminal Device(s), Small-diameter	C New Technology Group 12
FY2027	P Anterior Tibial Artery, Right	3 Percutaneous	T Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)	A New Technology Group 10
FY2027	Q Anterior Tibial Artery, Left	3 Percutaneous	N Intraluminal Device(s), Small-diameter	C New Technology Group 12
FY2027	Q Anterior Tibial Artery, Left	3 Percutaneous	T Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)	A New Technology Group 10
FY2027	R Posterior Tibial Artery, Right	3 Percutaneous	N Intraluminal Device(s), Small-diameter	C New Technology Group 12
FY2027	R Posterior Tibial Artery, Right	3 Percutaneous	T Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)	A New Technology Group 10
FY2027	S Posterior Tibial Artery, Left	3 Percutaneous	N Intraluminal Device(s), Small-diameter	C New Technology Group 12
FY2027	S Posterior Tibial Artery, Left	3 Percutaneous	T Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)	A New Technology Group 10
FY2027	T Peroneal Artery, Right	3 Percutaneous	N Intraluminal Device(s), Small-diameter	C New Technology Group 12
FY2027	T Peroneal Artery, Right	3 Percutaneous	T Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)	A New Technology Group 10
FY2027	U Peroneal Artery, Left	3 Percutaneous	N Intraluminal Device(s), Small-diameter	C New Technology Group 12
FY2027	U Peroneal Artery, Left	3 Percutaneous	T Intraluminal Device, Everolimus-eluting Resorbable Scaffold(s)	A New Technology Group 10
No change	W Thoracic Aorta, Descending X Thoracic Aorta, Ascending/Arch	3 Percutaneous	9 Intraluminal Device, Expandable	B New Technology Group 11

X28

No change	<i>Section</i>	X	New Technology		
	<i>Body System</i>	2	Cardiovascular System		
	<i>Operation</i>	8	Division: Cutting into a body part, without draining fluids and/or gases from the body part, in order to separate or transect a body part		
Heading	<i>Body Part</i>		<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	F Aortic Valve		3 Percutaneous	V Intraluminal Bioprosthetic Valve Leaflet Splitting Technology in Existing Valve	A New Technology Group 10
No change	F Aortic Valve		3 Percutaneous	W Leaflet Laceration, Radiofrequency Energy	B New Technology Group 11
FY2027	M Ventricular Septum		3 Percutaneous	D Transcatheter Septal Scoring Technique	C New Technology Group 12

X2H

No change	<i>Section</i>	X	New Technology	
	<i>Body System</i>	2	Cardiovascular System	
	<i>Operation</i>	H	Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	0 Inferior Vena Cava	3 Percutaneous	B Volume Sensor Management Device	B New Technology Group 11
No change	0 Inferior Vena Cava 1 Superior Vena Cava	3 Percutaneous	R Intraluminal Device, Bioprosthetic Valve	9 New Technology Group 9
No change	1 Superior Vena Cava	3 Percutaneous	X Temporary Phrenic Nerve/Diaphragm Stimulation Electrodes	B New Technology Group 11
No change	2 Femoral Vein, Right 3 Femoral Vein, Left	0 Open	R Intraluminal Device, Bioprosthetic Valve	9 New Technology Group 9
FY2027	4 Innominate Vein, Left	3 Percutaneous	M Temporary Intraluminal Device, Venous Angle Decompression using Impeller Pump	C New Technology Group 12
No change	6 Atrium, Right K Ventricle, Right	3 Percutaneous	V Intracardiac Pacemaker, Dual-Chamber	9 New Technology Group 9
No change	L Axillary Artery, Right M Axillary Artery, Left	0 Open	F Conduit to Short-term External Heart Assist System	9 New Technology Group 9
No change	M Ventricular Septum V Ventricle, Right	3 Percutaneous	G Defibrillator Lead, Lumenless Small-diameter	B New Technology Group 11
No change	N Ventricle, Left	3 Percutaneous	7 Endocardiac Pacing Electrode	B New Technology Group 11
No change	P Anterior Tibial Artery, Right Q Anterior Tibial Artery, Left R Posterior Tibial Artery, Right S Posterior Tibial Artery, Left T Peroneal Artery, Right U Peroneal Artery, Left	3 Percutaneous	8 Intraluminal Device, Temporary	B New Technology Group 11
No change	X Thoracic Aorta, Ascending	0 Open	F Conduit to Short-term External Heart Assist System	9 New Technology Group 9

X2R

No change	<i>Section</i>	X	New Technology	
	<i>Body System</i>	2	Cardiovascular System	
	<i>Operation</i>	R	Replacement: Putting in or on biological or synthetic material that physically takes the place and/or function of all or a portion of a body part	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	5 Upper Extremity Artery, Right 6 Upper Extremity Artery, Left 7 Lower Extremity Artery, Right 8 Lower Extremity Artery, Left	0 Open	W Bioengineered Human Acellular Vessel	A New Technology Group 10
FY2027	F Aortic Valve	3 Percutaneous	L Zooplastic Tissue, with Integrated Native Leaflet Clipping Locators	C New Technology Group 12
FY2027	G Mitral Valve	3 Percutaneous	F Bioprosthetic Valve, Balloon-expandable with Dock	C New Technology Group 12
FY2027	H Pulmonary Valve	0 Open	G Synthetic Substitute, Size-Adjustable	C New Technology Group 12
No change	J Tricuspid Valve	3 Percutaneous	R Multi-plane Flex Technology Bioprosthetic Valve	A New Technology Group 10
No change	X Thoracic Aorta, Arch	0 Open	N Branched Synthetic Substitute with Intraluminal Device	7 New Technology Group 7

X2V

No change	<i>Section</i> X New Technology			
	<i>Body System</i> 2 Cardiovascular System			
	<i>Operation</i> V Restriction: Partially closing an orifice or the lumen of a tubular body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	7 Coronary Sinus	3 Percutaneous	Q Reduction Device	7 New Technology Group 7
No change	E Descending Thoracic Aorta and Abdominal Aorta	3 Percutaneous	S Branched Intraluminal Device, Manufactured Integrated System, Four or More Arteries	A New Technology Group 10
FY2027	J Thoracic Aorta, Ascending and Arch	3 Percutaneous	H Branched Intraluminal Device, Integrated System with Innominate Branch	C New Technology Group 12
No change	W Thoracic Aorta, Descending	0 Open	N Branched Synthetic Substitute with Intraluminal Device	7 New Technology Group 7
FY2027	W Thoracic Aorta, Descending	3 Percutaneous	J Branched Intraluminal Device, Integrated System Extension	C New Technology Group 12
FY2027	X Thoracic Aorta, Arch	0 Open	K Branched Intraluminal Device, with Conical Collar	C New Technology Group 12
No change	Y Thoracic Aortic Arch and Descending Thoracic Aorta	0 Open	6 Intraluminal Device, Uncovered with Support Cuff	B New Technology Group 11

XD2

FY2026

<i>Section</i>	X	New Technology
<i>Body System</i>	D	Gastrointestinal System
<i>Operation</i>	2	Monitoring: Determining the level of a physiological or physical function repetitively over a period of time

XEZ

FY2027	Section X New Technology Body System E Physiological Systems and Anatomical Regions Operation Z Other Procedures: Methodologies which attempt to remediate or cure a disorder or disease			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2027	5 Chest, Abdomen and Pelvis	X External	K Computer-Aided Triage and Notification for Imaging Abnormalities in Computed Tomography	C New Technology Group 12
FY2027	D Pericardial Cavity	3 Percutaneous	Q Pericardial Cavity Access using Blunt-tip Concealed Needle with Mechanical Gripping Mechanism	C New Technology Group 12
FY2027	J Coronary Artery/Arteries	3 Percutaneous	N Coronary Artery Access using Image-Guided Crossing and Re-entry System	C New Technology Group 12
FY2027	U Spinal Canal	3 Percutaneous	H Computer-Aided Guidance for Intraprocedural Navigation using Ultrasound Imaging with Continuous Needle Tracking	C New Technology Group 12
FY2027	Z None	X External	J High Dimensional Mixture-of-Experts Computer-aided Assessment of Inflammatory Response and Organ Function, for Notification and Triage L Computer-Aided Detection and Notification for Imaging Abnormalities in Echocardiography M Computer-Aided Detection and Notification for Abnormalities in Electrocardiogram P Cardiac Conduction Mechanism, Computer-aided Guidance for Three Dimensional Intraprocedural Navigation using Fluoroscopic Imaging R Computer-Aided Detection and Notification of Cardiac Abnormalities using Vital Signs S Cardiac Conduction Mechanism, Computer-aided Intraprocedural Visualization for Guidance	C New Technology Group 12

XFJ

No change	Section X New Technology			
	Body System F Hepatobiliary System and Pancreas			
	Operation J Inspection: Visually and/or manually exploring a body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2027	B Hepatobiliary Duct	3 Percutaneous 4 Percutaneous Endoscopic	C Single-use Choledochoscope	C New Technology Group 12
FY2027	B Hepatobiliary Duct	8 Via Natural or Artificial Opening Endoscopic	A Single-use Duodenoscope	7 New Technology Group 7
FY2027	B Hepatobiliary Duct	8 Via Natural or Artificial Opening Endoscopic	B Single-use Cholangioscope	C New Technology Group 12
FY2027	D Pancreatic Duct	3 Percutaneous 4 Percutaneous Endoscopic	C Single-use Choledochoscope	C New Technology Group 12
FY2027	D Pancreatic Duct	8 Via Natural or Artificial Opening Endoscopic	A Single-use Duodenoscope	7 New Technology Group 7
FY2027	D Pancreatic Duct	8 Via Natural or Artificial Opening Endoscopic	B Single-use Cholangioscope	C New Technology Group 12

XHH

No change	<i>Section</i>	X	New Technology		
	<i>Body System</i>	H	Skin, Subcutaneous Tissue, Fascia and Breast		
	<i>Operation</i>	H	Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part		
Heading	<i>Body Part</i>		<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	8 Subcutaneous Tissue and Fascia, Chest		0 Open	H Ultrasound Transmitter and Battery for Endocardiac Pacing Electrode	B New Technology Group 11
FY2027	8 Subcutaneous Tissue and Fascia, Chest		0 Open	J Contractility Modulation Device with Defibrillator Generator	C New Technology Group 12

XRG

No change	<i>Section</i>	X	New Technology	
	<i>Body System</i>	R	Joints	
	<i>Operation</i>	G	Fusion: Joining together portions of an articular body part rendering the articular body part immobile	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	1 Cervical Vertebral Joint 2 Cervical Vertebral Joints, 2 or more 4 Cervicothoracic Vertebral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	R Interbody Fusion Device, Custom-Made Anatomically Designed	B New Technology Group 11
FY2027	A Thoracolumbar Vertebral Joint B Lumbar Vertebral Joint C Lumbar Vertebral Joints, 2 or more D Lumbosacral Joint	0 Open	E Facet Joint Fusion Device, Paired Titanium Cages	A New Technology Group 10
No change	E Sacroiliac Joint, Right	0 Open	5 Internal Fixation Device with Tulip Connector	8 New Technology Group 8
No change	E Sacroiliac Joint, Right	0 Open	H Internal Fixation Device, Bone-Density-Specific Thread and Porosity Pattern	B New Technology Group 11
No change	E Sacroiliac Joint, Right	3 Percutaneous	5 Internal Fixation Device with Tulip Connector	8 New Technology Group 8
No change	E Sacroiliac Joint, Right	3 Percutaneous	H Internal Fixation Device, Bone-Density-Specific Thread and Porosity Pattern	B New Technology Group 11
No change	F Sacroiliac Joint, Left	0 Open	5 Internal Fixation Device with Tulip Connector	8 New Technology Group 8
No change	F Sacroiliac Joint, Left	0 Open	H Internal Fixation Device, Bone-Density-Specific Thread and Porosity Pattern	B New Technology Group 11
No change	F Sacroiliac Joint, Left	3 Percutaneous	5 Internal Fixation Device with Tulip Connector	8 New Technology Group 8
No change	F Sacroiliac Joint, Left	3 Percutaneous	H Internal Fixation Device, Bone-Density-Specific Thread and Porosity Pattern	B New Technology Group 11
No change	J Ankle Joint, Right	0 Open	B Internal Fixation Device, Open-truss Design	9 New Technology Group 9
No change	J Ankle Joint, Right	0 Open	C Internal Fixation Device, Gyroid-Sheet Lattice Design	A New Technology Group 10
No change	K Ankle Joint, Left	0 Open	B Internal Fixation Device, Open-truss Design	9 New Technology Group 9
No change	K Ankle Joint, Left	0 Open	C Internal Fixation Device, Gyroid-Sheet Lattice Design	A New Technology Group 10
No change	L Tarsal Joint, Right	0 Open	B Internal Fixation Device, Open-truss Design	9 New Technology Group 9
No change	L Tarsal Joint, Right	0 Open	C Internal Fixation Device, Gyroid-Sheet Lattice Design	A New Technology Group 10
No change	M Tarsal Joint, Left	0 Open	B Internal Fixation Device, Open-truss Design	9 New Technology Group 9
No change	M Tarsal Joint, Left	0 Open	C Internal Fixation Device, Gyroid-Sheet Lattice Design	A New Technology Group 10

XRH

No change	<i>Section</i>	X New Technology		
	<i>Body System</i>	R Joints		
	<i>Operation</i>	H Insertion: Putting in a nonbiological appliance that monitors, assists, performs, or prevents a physiological function but does not physically take the place of a body part		
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2027	1 Cervical Vertebral Joint	0 Open	G Molybdenum Rhenium Alloy Spinal Stabilization Device	B New Technology Group 11
FY2027	1 Cervical Vertebral Joint	0 Open	N Carbon/PEEK Spinal Stabilization Device	C New Technology Group 12
FY2027	1 Cervical Vertebral Joint	3 Percutaneous	G Molybdenum Rhenium Alloy Spinal Stabilization Device	B New Technology Group 11
FY2027	1 Cervical Vertebral Joint	3 Percutaneous	N Carbon/PEEK Spinal Stabilization Device	C New Technology Group 12
FY2027	1 Cervical Vertebral Joint	4 Percutaneous Endoscopic	G Molybdenum Rhenium Alloy Spinal Stabilization Device	B New Technology Group 11
FY2027	1 Cervical Vertebral Joint	4 Percutaneous Endoscopic	N Carbon/PEEK Spinal Stabilization Device	C New Technology Group 12
FY2027	2 Cervical Vertebral Joints, 2 or more	0 Open	G Molybdenum Rhenium Alloy Spinal Stabilization Device	B New Technology Group 11
FY2027	2 Cervical Vertebral Joints, 2 or more	0 Open	N Carbon/PEEK Spinal Stabilization Device	C New Technology Group 12
FY2027	2 Cervical Vertebral Joints, 2 or more	3 Percutaneous	G Molybdenum Rhenium Alloy Spinal Stabilization Device	B New Technology Group 11
FY2027	2 Cervical Vertebral Joints, 2 or more	3 Percutaneous	N Carbon/PEEK Spinal Stabilization Device	C New Technology Group 12
FY2027	2 Cervical Vertebral Joints, 2 or more	4 Percutaneous Endoscopic	G Molybdenum Rhenium Alloy Spinal Stabilization Device	B New Technology Group 11
FY2027	2 Cervical Vertebral Joints, 2 or more	4 Percutaneous Endoscopic	N Carbon/PEEK Spinal Stabilization Device	C New Technology Group 12
FY2027	4 Cervicothoracic Vertebral Joint	0 Open	G Molybdenum Rhenium Alloy Spinal Stabilization Device	B New Technology Group 11
FY2027	4 Cervicothoracic Vertebral Joint	0 Open	N Carbon/PEEK Spinal Stabilization Device	C New Technology Group 12
FY2027	4 Cervicothoracic Vertebral Joint	3 Percutaneous	G Molybdenum Rhenium Alloy Spinal Stabilization Device	B New Technology Group 11
FY2027	4 Cervicothoracic Vertebral Joint	3 Percutaneous	N Carbon/PEEK Spinal Stabilization Device	C New Technology Group 12
FY2027	4 Cervicothoracic Vertebral Joint	4 Percutaneous Endoscopic	G Molybdenum Rhenium Alloy Spinal Stabilization Device	B New Technology Group 11
FY2027	4 Cervicothoracic Vertebral Joint	4 Percutaneous Endoscopic	N Carbon/PEEK Spinal Stabilization Device	C New Technology Group 12
No change	6 Thoracic Vertebral Joint	0 Open	F Carbon/PEEK Spinal Stabilization Device, Pedicle Based	A New Technology Group 10

No change	6 Thoracic Vertebral Joint	0 Open	G Molybdenum Rhenium Alloy Spinal Stabilization Device	B New Technology Group 11
FY2027	6 Thoracic Vertebral Joint	0 Open	N Carbon/PEEK Spinal Stabilization Device	C New Technology Group 12
No change	6 Thoracic Vertebral Joint	3 Percutaneous	F Carbon/PEEK Spinal Stabilization Device, Pedicle Based	A New Technology Group 10
No change	6 Thoracic Vertebral Joint	3 Percutaneous	G Molybdenum Rhenium Alloy Spinal Stabilization Device	B New Technology Group 11
FY2027	6 Thoracic Vertebral Joint	3 Percutaneous	N Carbon/PEEK Spinal Stabilization Device	C New Technology Group 12
No change	6 Thoracic Vertebral Joint	4 Percutaneous Endoscopic	F Carbon/PEEK Spinal Stabilization Device, Pedicle Based	A New Technology Group 10
No change	6 Thoracic Vertebral Joint	4 Percutaneous Endoscopic	G Molybdenum Rhenium Alloy Spinal Stabilization Device	B New Technology Group 11
FY2027	6 Thoracic Vertebral Joint	4 Percutaneous Endoscopic	N Carbon/PEEK Spinal Stabilization Device	C New Technology Group 12
No change	7 Thoracic Vertebral Joints, 2 to 7 8 Thoracic Vertebral Joints, 8 or more A Thoracolumbar Vertebral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	F Carbon/PEEK Spinal Stabilization Device, Pedicle Based	A New Technology Group 10
No change	B Lumbar Vertebral Joint	0 Open	1 Posterior Spinal Motion Preservation Device	8 New Technology Group 8
No change	B Lumbar Vertebral Joint C Lumbar Vertebral Joints, 2 or more	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	F Carbon/PEEK Spinal Stabilization Device, Pedicle Based	A New Technology Group 10
No change	D Lumbosacral Joint	0 Open	1 Posterior Spinal Motion Preservation Device	8 New Technology Group 8
No change	D Lumbosacral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	F Carbon/PEEK Spinal Stabilization Device, Pedicle Based	A New Technology Group 10

XW0

No change	<i>Section</i>	X	New Technology		
	<i>Body System</i>	W	Anatomical Regions		
	<i>Operation</i>	0	Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products		
Heading	<i>Body Part</i>		<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	1 Subcutaneous Tissue		3 Percutaneous	1 Daratumumab and Hyaluronidase-fihj	8 New Technology Group 8
No change	1 Subcutaneous Tissue		3 Percutaneous	2 Talquetamab Antineoplastic	9 New Technology Group 9
No change	1 Subcutaneous Tissue		3 Percutaneous	4 Teclistamab Antineoplastic	8 New Technology Group 8
FY2027	1 Subcutaneous Tissue		3 Percutaneous	4 Elamipretide	C New Technology Group 12
No change	1 Subcutaneous Tissue		3 Percutaneous	6 Dasiglucagon	A New Technology Group 10
No change	1 Subcutaneous Tissue		3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	1 Subcutaneous Tissue		3 Percutaneous	G REGN-COV2 Monoclonal Antibody H Other New Technology Monoclonal Antibody K Leronlimab Monoclonal Antibody	6 New Technology Group 6
No change	1 Subcutaneous Tissue		3 Percutaneous	L Elranatamab Antineoplastic	9 New Technology Group 9
No change	1 Subcutaneous Tissue		3 Percutaneous	S COVID-19 Vaccine Dose 1	6 New Technology Group 6
No change	1 Subcutaneous Tissue		3 Percutaneous	S Epcoritamab Monoclonal Antibody	9 New Technology Group 9
No change	1 Subcutaneous Tissue		3 Percutaneous	T COVID-19 Vaccine Dose 2	6 New Technology Group 6
No change	1 Subcutaneous Tissue		3 Percutaneous	T Rozanolixizumab-noli Monoclonal Antibody	B New Technology Group 11
No change	1 Subcutaneous Tissue		3 Percutaneous	U COVID-19 Vaccine	6 New Technology Group 6
No change	1 Subcutaneous Tissue		3 Percutaneous	V COVID-19 Vaccine Dose 3	7 New Technology Group 7
No change	1 Subcutaneous Tissue		3 Percutaneous	W Caplacizumab	5 New Technology Group 5
No change	1 Subcutaneous Tissue		3 Percutaneous	W COVID-19 Vaccine Booster	7 New Technology Group 7
No change	2 Muscle		0 Open	D Engineered Allogeneic Thymus Tissue	8 New Technology Group 8
No change	2 Muscle		3 Percutaneous	S COVID-19 Vaccine Dose 1 T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
No change	2 Muscle		3 Percutaneous	V COVID-19 Vaccine Dose 3 W COVID-19 Vaccine Booster Y Other New Technology Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein		3 Percutaneous	0 Spesolimab Monoclonal Antibody	8 New Technology Group 8
No change	3 Peripheral Vein		3 Percutaneous	0 Alpha1-proteinase Inhibitor 1 Anitocabtagene Autoleucel Immunotherapy	B New Technology Group 11

No change	3 Peripheral Vein	3 Percutaneous	3 Bentracimab, Ticagrelor Reversal Agent 4 Cefepime-taniborbactam Anti-infective	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	5 Mosunetuzumab Antineoplastic	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	5 Ceftobiprole Medocaril Anti-infective	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	6 Afamitresgene Autoleucel Immunotherapy	8 New Technology Group 8
FY2027	3 Peripheral Vein	3 Percutaneous	6 Landiolol Antiarrhythmic	C New Technology Group 12
No change	3 Peripheral Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	3 Peripheral Vein	3 Percutaneous	7 Tabelecleucel Immunotherapy	8 New Technology Group 8
FY2027	3 Peripheral Vein	3 Percutaneous	7 Zimislecel Allogeneic Stem Cell-Derived Islet Cell Therapy	C New Technology Group 12
No change	3 Peripheral Vein	3 Percutaneous	8 Treosulfan	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	8 Obecabtagene Autoleucel	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	9 Inebilizumab-cdon	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	9 Odronektamab Antineoplastic	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	A Ciltacabtagene Autoleucel	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	B Orca-T Allogeneic T-cell Immunotherapy	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	C Zanidatamab Antineoplastic D Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	F Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	F Valoctocogene Roxaparvovec-rvox	B New Technology Group 11
No change	3 Peripheral Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5

No change	3 Peripheral Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	K Sulbactam-Durlobactam	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	L Lileucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	M Emapalumab-Izsg Anti-IFNy Monoclonal Antibody	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	N Tarlatamab-dlle Antineoplastic	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	P Glofitamab Antineoplastic	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	P Aztreonam-avibactam Anti-infective	B New Technology Group 11
No change	3 Peripheral Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	Q Posoleucel	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	Q Iloprost	B New Technology Group 11
No change	3 Peripheral Vein	3 Percutaneous	R Rezafungin	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	R Letetresgene Autoleucel	B New Technology Group 11
No change	3 Peripheral Vein	3 Percutaneous	S Iobenguane I-131 Antineoplastic W Caplacizumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	W Fosfomycin Anti-infective	B New Technology Group 11
No change	4 Central Vein	3 Percutaneous	0 Spesolimab Monoclonal Antibody	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	0 Alpha1-proteinase Inhibitor 1 Anitocabtagene Autoleucel Immunotherapy	B New Technology Group 11
No change	4 Central Vein	3 Percutaneous	3 Bentracimab, Ticagrelor Reversal Agent 4 Cefepime-taniborbactam Anti-infective	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	5 Mosunetuzumab Antineoplastic	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	5 Ceftobiprole Medocaril Anti-infective	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	6 Afamitresgene Autoleucel Immunotherapy	8 New Technology Group 8
FY2027	4 Central Vein	3 Percutaneous	6 Landiolol Antiarrhythmic	C New Technology Group 12
No change	4 Central Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	4 Central Vein	3 Percutaneous	7 Tabelecleucel Immunotherapy 8 Treosulfan	8 New Technology Group 8

No change	4 Central Vein	3 Percutaneous	8 Obecabtagene Autoleucel	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	9 Inebilizumab-cdon	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	9 Odronektamab Antineoplastic	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	A Ciltacabtagene Autoleucel	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	B Orca-T Allogeneic T-cell Immunotherapy	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	C Zanidatamab Antineoplastic	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	F Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	F Valoctocogene Roxaparvovec-rvox	B New Technology Group 11
No change	4 Central Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	K Sulbactam-Durlobactam	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	L Lifileucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	M Emapalumab-Izsg Anti-IFNγ Monoclonal Antibody	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	N Tarlatamab-dlle Antineoplastic	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	P Glofitamab Antineoplastic	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	P Aztreonam-avibactam Anti-infective	B New Technology Group 11
No change	4 Central Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic	5 New Technology Group 5

No change	4 Central Vein	3 Percutaneous	Q Posoleucel	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	Q Iloprost	B New Technology Group 11
No change	4 Central Vein	3 Percutaneous	R Rezafungin	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	R Letetresgene Autoleucel	B New Technology Group 11
No change	4 Central Vein	3 Percutaneous	S Iobenguane I-131 Antineoplastic W Caplacizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	W Fosfomycin Anti-infective	B New Technology Group 11
No change	5 Peripheral Artery	3 Percutaneous	4 Stem Cells, Somatic	B New Technology Group 11
No change	5 Peripheral Artery	3 Percutaneous	T Melphalan Hydrochloride Antineoplastic	9 New Technology Group 9
No change	6 Cerebral Ventricle	3 Percutaneous	2 CPI-601 Enzyme Replacement Therapy	B New Technology Group 11
No change	D Mouth and Pharynx	X External	3 Maribavir Anti-infective	8 New Technology Group 8
No change	D Mouth and Pharynx	X External	8 Uridine Triacetate	2 New Technology Group 2
No change	D Mouth and Pharynx	X External	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	J Quizartinib Antineoplastic	9 New Technology Group 9
No change	D Mouth and Pharynx	X External	K Sabizabulin	8 New Technology Group 8
No change	D Mouth and Pharynx	X External	M Baricitinib	6 New Technology Group 6
No change	D Mouth and Pharynx	X External	N SER-109	9 New Technology Group 9
No change	D Mouth and Pharynx	X External	V Xanomeline and Trospium Chloride	B New Technology Group 11
Revise from	E Ear(s)	3 Percutaneous	3 DB-OTO via Intracochlear Infusion	B New Technology Group 11
Revise to	E Ear(s)	3 Percutaneous	3 Lunsotogene Parvec-cwha via Intracochlear Infusion	B New Technology Group 11
No change	G Upper GI	7 Via Natural or Artificial Opening	3 Maribavir Anti-infective K Sabizabulin	8 New Technology Group 8
No change	G Upper GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
No change	G Upper GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
No change	H Lower GI	7 Via Natural or Artificial Opening	3 Maribavir Anti-infective K Sabizabulin	8 New Technology Group 8
No change	H Lower GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
No change	H Lower GI	7 Via Natural or Artificial Opening	X Broad Consortium Microbiota-based Live Biotherapeutic Suspension	8 New Technology Group 8
No change	H Lower GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
No change	J Coronary Artery, One Artery K Coronary Artery, Two Arteries L Coronary Artery, Three Arteries M Coronary Artery, Four or More Arteries	3 Percutaneous	H Paclitaxel-Coated Balloon Technology, One Balloon J Paclitaxel-Coated Balloon Technology, Two Balloons K Paclitaxel-Coated Balloon Technology, Three Balloons L Paclitaxel-Coated Balloon Technology, Four or More Balloons	A New Technology Group 10
No change	Q Cranial Cavity and Brain	3 Percutaneous	1 Eladocogene exuparvovec	6 New Technology Group 6
FY2027	Q Cranial Cavity and Brain	3 Percutaneous	5 Ifezuntirgene Inilparvovec	C New Technology Group 12

FY2027	U Joints	0 Open	C Recombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold	C New Technology Group 12
No change	U Joints	0 Open	G Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System	A New Technology Group 10
No change	U Joints	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	X Peptide Enhanced Bone Void Filler	B New Technology Group 11
FY2027	V Bones	0 Open	B Vancomycin-eluting Bone Void Filler	C New Technology Group 12
Revise from	V Bones	0 Open	P Antibiotic-eluting Bone Void Filler	7 New Technology Group 7
Revise to	V Bones	0 Open	P Gentamicin-eluting Bone Void Filler	7 New Technology Group 7
No change	V Bones	3 Percutaneous	W AGN1 Bone Void Filler	A New Technology Group 10

XW1

No change	Section X New Technology Body System W Anatomical Regions Operation 1 Transfusion: Putting in blood or blood products			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	3 Peripheral Vein	3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	7 Marnetegrane Autotemcel	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	B Betibeglogene Autotemcel C Omidubicel	8 New Technology Group 8
FY2027	3 Peripheral Vein	3 Percutaneous	E Hyperimmune Globulin	7 New Technology Group 7
FY2027	3 Peripheral Vein	3 Percutaneous	G Atidarsagene Autotemcel	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	H Lovotibeglogene Autotemcel	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	J Exagamlogene Autotemcel	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	S Mozafancogene Autotemcel Y Nonautologous (Human) Fibrinogen Concentrate, Shelf-stable	B New Technology Group 11
No change	4 Central Vein	3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	7 Marnetegrane Autotemcel	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	B Betibeglogene Autotemcel C Omidubicel	8 New Technology Group 8
FY2027	4 Central Vein	3 Percutaneous	E Hyperimmune Globulin	7 New Technology Group 7
Revise from	4 Central Vein	3 Percutaneous	F OTL-103 G Atidarsagene Autotemcel	8 New Technology Group 8
Revise to	4 Central Vein	3 Percutaneous	F Etuvetidigene Autotemcel G Atidarsagene Autotemcel	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	H Lovotibeglogene Autotemcel	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	J Exagamlogene Autotemcel	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	S Mozafancogene Autotemcel Y Nonautologous (Human) Fibrinogen Concentrate, Shelf-stable	B New Technology Group 11

XXE

No change	Section X New Technology Body System X Physiological Systems Operation E Measurement: Determining the level of a physiological or physical function at a point in time			
Heading	Body Part	Approach	Device / Substance / Technology	Qualifier
No change	0 Central Nervous	X External	0 Intracranial Vascular Activity, Computer-aided Assessment	7 New Technology Group 7
No change	0 Central Nervous	X External	1 Intracranial Cerebrospinal Fluid Flow, Computer-aided Triage and Notification	A New Technology Group 10
No change	0 Central Nervous	X External	4 Brain Electrical Activity, Computer-aided Semiologic Analysis	8 New Technology Group 8
No change	2 Cardiac	X External	1 Output, Computer-aided Assessment	9 New Technology Group 9
FY2027	2 Cardiac	X External	H Cardiac Conduction Mechanism, Computer-aided Mapping for Planning	C New Technology Group 12
No change	3 Arterial	X External	2 Pulmonary Artery Flow, Computer-aided Triage and Notification	7 New Technology Group 7
No change	3 Arterial	X External	5 Coronary Artery Flow, Quantitative Flow Ratio Analysis 6 Coronary Artery Flow, Computer-aided Valve Modeling and Notification	8 New Technology Group 8
No change	5 Circulatory	X External	2 Infection, Phenotypic Fully Automated Rapid Susceptibility Technology with Controlled Inoculum	A New Technology Group 10
No change	5 Circulatory	X External	3 Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction	8 New Technology Group 8
No change	5 Circulatory	X External	4 Infection, Positive Blood Culture Small Molecule Sensor Array Technology 5 Immune Response, Whole Blood Cellular Assessment via Microfluidic Deformability	A New Technology Group 10
No change	5 Circulatory	X External	B Infection and Immune Response, Gene Expression Testing System	B New Technology Group 11
FY2027	5 Circulatory	X External	V Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection	7 New Technology Group 7
No change	5 Circulatory	X External	Y Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology	9 New Technology Group 9
No change	9 Nose	7 Via Natural or Artificial Opening	U Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction	7 New Technology Group 7

No change

Z None	X External	A Macronutrient Content, Computer-aided Assessment for Nutrition Management C Infection, Computer-aided Triage and Notification	B New Technology Group 11
---------------	-------------------	--	----------------------------------